Cellyan Biotechnology Co., Ltd
HKPD Healthcare Medical Distribution
Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.
Follow HKPD
Cellyan Biotechnology Co., Ltd (HKPD) Piotroski F-score
Cellyan Biotechnology Co., Ltd's Piotroski F-score for fiscal 2026 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 3 | (1.00) |
| FY2025 | 4 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (10.21%) | (0.30%) | Fail | 0 |
| Positive operating cash flow | (751.60k) | 569.20k | Fail | 0 |
| Rising return on assets | (10.21%) | (0.30%) | Fail | 0 |
| Cash flow above net income | 384.40k | 596.30k | Pass | 1 |
| Falling long-term leverage | 0.01 | 0.17 | Pass | 1 |
| Rising current ratio | 3.86 | 2.99 | Pass | 1 |
| No new shares issued | 16,350,000 | 10,205,000 | Fail | 0 |
| Rising gross margin | 10.32% | 11.89% | Fail | 0 |
| Rising asset turnover | 1.21 | 2.25 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CAH Cardinal Health, Inc. compare | 7 |
| YI 111, Inc. Sponsored ADR compare | 5 |
| COSM Cosmos Health Inc. compare | 5 |
| AHG Akso Health Group Sponsored ADR compare | 5 |
| HSIC Henry Schein, Inc. compare | 5 |
| FOCL FocalTherics compare | 3 |
| HKPD Cellyan Biotechnology Co., Ltd | 3 |
| SNYRQ Synergy CHC Corp. compare | 2 |
| ACH Accendra Health, Inc. compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover